ArticleCanadian liver journal2025
Fulminant liver failure due to Epstein-Barr virus in immunodeficiency disorders.
Article in Canadian liver journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epstein-Barr virus and hepatic failure: pathogenesis, clinical manifestations, and management.Frontiers in immunology · 2026Review
- Genetic and autoimmune predispositions to fulminant viral hepatitis in children.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The majority of patients with Epstein-Barr virus (EBV)-associated hepatitis have a mild clinical course; most infections resolve spontaneously. However, in rare cases, or in patients with underlying immune deficits, outcomes can be fatal. Methods: We used a single-centre case series. Results: In this report, we describe two cases of acute EBV hepatitis. The first patient developed fulminant hepatitis with multi-organ failure and severe immune dysregulation; he died despite maximal intensive-care management. Post-mortem, his bone marrow biopsy results revealed an X-linked lymphoproliferative disease. This primary immunodeficiency impairs the body's ability to control EBV infection and is a risk factor for developing an EBV-positive T-cell lymphoma in childhood. The second patient presented with hepatitis, cytopenias, and hepatosplenomegaly in the context of persistent EBV viremia and responded well to treatment (dexamethasone, rituximab, and supportive care). Immunodeficiency testing was negative in this case. Conclusions: Prompt multidisciplinary management is recommended in cases of severe EBV-associated liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.